Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$834 Mln
P/E Ratio
--
P/B Ratio
1.72
Industry P/E
--
Debt to Equity
0.1
ROE
-0.6 %
ROCE
-56.26 %
Div. Yield
0 %
Book Value
5.38
EPS
-3.14
CFO
$-167.46 Mln
EBITDA
$-833.86 Mln
Net Profit
$-834.25 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Arcus Biosciences (RCUS)
| -48.22 | -14.99 | -45.05 | -47.16 | -37.28 | -23.84 | -- |
|
BSE Sensex*
| 1.79 | 3.57 | 5.03 | 8.98 | 11.21 | 21.06 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Arcus Biosciences (RCUS)
| -21.88 | -7.64 | -48.90 | 55.89 | 157.03 | -6.22 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.59 | 9,973.38 | 20.56 | 23.13 | |
| 288.99 | 8,956.07 | 23.48 | 58.42 | |
| 25.13 | 9,559.25 | -- | -28.77 | |
| 100.68 | 10,030.35 | 30.81 | 14.16 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney... cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California. Address: 3928 Point Eden Way, Hayward, CA, United States, 94545 Read more
Co-Founder, Chairman & CEO
Dr. Terry J. Rosen Ph.D.
Co-Founder, Chairman & CEO
Dr. Terry J. Rosen Ph.D.
Headquarters
Hayward, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Arcus Biosciences Inc (RCUS) stood at $ 1,150 Mln as on 31-Dec-24
The share price of Arcus Biosciences Inc (RCUS) is $7.71 (NYSE) as of 21-Apr-2025 16:22 EDT. Arcus Biosciences Inc (RCUS) has given a return of -37.28% in the last 3 years.
Arcus Biosciences Inc (RCUS) has a market capitalisation of $ 834 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Arcus Biosciences Inc (RCUS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Arcus Biosciences Inc (RCUS) and enter the required number of quantities and click on buy to purchase the shares of Arcus Biosciences Inc (RCUS).
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California. Address: 3928 Point Eden Way, Hayward, CA, United States, 94545
The CEO & director of Dr. Terry J. Rosen Ph.D.. is Arcus Biosciences Inc (RCUS), and CFO & Sr. VP is Dr. Terry J. Rosen Ph.D..
There is no promoter pledging in Arcus Biosciences Inc (RCUS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Arcus Biosciences Inc. (RCUS) | Ratios |
|---|---|
|
Return on equity(%)
|
-59.77
|
|
Operating margin(%)
|
-108.14
|
|
Net Margin(%)
|
-109.69
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Arcus Biosciences Inc (RCUS) was $0 Mln.
$-0.17
(
